ClinicalTrials.gg
RecruitingNCT06830499Updated May 27, 2026

Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

An observational study in AORTIC VALVE DISEASES and Bicuspid Aortic Valve (BAV), sponsored by Xijing Hospital. Recruiting at 4 sites in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Xijing Hospital · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
450
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.

Planned enrollment
9th of 13
450 · median 1,000
Started
2025
with 3 others
Observational
13 of 27
10 open now
Primary completion
2031-06
later than 13 of 17 live
Registered
20th of 27
by date
Lead sponsor
3 of 27
Xijing Hospital

Among the 27 studies in Aortic Valve Disease with a site in China, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 13 of the 17 other live ones, and was the 20th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Aortic Valve Disease with a site in China, or all of them as a file.
02

Study summary

Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China:A multi-center, retrospective and prospective, single arm, observational study

Read the detailed description

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Currently TAVR indication has expanded to intermediate and low-risk patients from inoperable or high-risk patients, through a rigorous series of clinical trials comparing TAVR with surgical aortic valve replacement (SAVR).

Despite 2020 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommended SAVR for patients with symptomatic severe AS aged \<65 years, the previous data from United States nationwide Vizient Clinical Data Base and Northern New England Cardiovascular Disease Group Consortium (NNECDSG) registry demonstrated dramatic growth in TAVR utilization in younger patients aged \<65 years from 2015 to 2021/2022, which is possibly driven by increased TAVR utilization in low surgical risk patients.

However, TAVR has never been systematically tested in young (\<65 years old), low-risk patients, with many unanswered questions, especially the safety and effectiveness of TAVR in patients with bicuspid aortic valves and the durability of transcatheter heart valves. Furthermore, we noticed that the patients between 65 years old and 70 years old accounted for 23.3% of all the TAVR patients and this patient subgroup were underrepresented in the previous study, which makes it necessary to also explore the interested endpoints in this subgroup.

The aim of this study is to establish the safety and efficacy of Sapien 3 TAVR in young (50\~70 years old) Chinese patients with severe symptomatic AS, including Type-1 bicuspid population and to explore the durability performance of Sapien 3 in this cohort.

03

Conditions studied

  • AORTIC VALVE DISEASES
  • Bicuspid Aortic Valve (BAV)

Keywords

  • TAVR
  • real-world
  • aortic valve stenosis
  • Sapien 3
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Young (50\~70 years old) Chinese patients with severe symptomatic AS, including Type-1 bicuspid population

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet ALL of the following inclusion criteria to be eligible for participation:

  • 50 years of age or older but ≤70 years old at time of consent.
  • Severe AS, defined as follows:

    a) For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a \<50%.

  • Tricuspid aortic valve stenosis and type-1 bicuspid aortic valve anatomy confirmed by MDCT.
  • The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.
  • Adequate iliofemoral access and acceptable level of vessel calcification and tortuosity for safe device implant.
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written as approved by the Institutional Review Board (IRB) of the respective clinical site.

Exclusion criteria

Exclusion Criteria:

Subjects are NOT eligible for participation if they meet ANY of the following exclusion criteria:

  • Any of the following: a. no calcification; b. challenging calcification based on physician's experience and discretion (Case Review Board would decide whether to exclude challenging calcification cases).
  • Aortic valve is a congenital unicuspid valve, congenital Type-0 or Type-2 bicuspid valve, or quadricuspid valve.
  • Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR.
  • Evidence of an acute myocardial infarction ≤ 1 month (30 days), with evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia.
  • Need for open heart surgery (including severe aortic regurgitation, mitral regurgitation or stenosis, or tricuspid regurgitation, congenital heart disease, AF, complex coronary artery disease).
  • Aortic disease: a. bicuspid aortic valve with an ascending aorta diameter ≥ 45mm b. tricuspid aortic valve with an ascending aorta diameter ≥ 50mm.
  • Pre-existing mechanical or bioprosthetic valve in any position.
  • Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit.
  • Emergency interventional/surgical procedures within 30 days of the valve implant procedure.
  • Hypertrophic cardiomyopathy with or without obstruction.
  • Ventricular dysfunction with \< 30%.
  • Cardiac imaging (echo, CT, and/or MRI) evidence of ventricular mass, thrombus or vegetation.
  • Inability (including allergy) to heparin, iodine contrast agent, warfarin or NOAC, aspirin or clopidogrel.
  • Stroke or (TIA) within 180 days of the valve implant procedure.
  • Renal replacement therapy at the time of screening.
  • Severe lung disease ( \< 50% predicted) or currently on home oxygen.
  • Estimated \< 24 months.
  • Currently participating in an drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • 300 retrospectively enrolled patients

    Procedure: TAVR

    Procedure: Transcatheter Aortic Valve Replacement (TAVR)

  • 150 prospectively enrolled patients

    Procedure: TAVR

    Procedure: Transcatheter Aortic Valve Replacement (TAVR)

Interventions

  • ProcedureTranscatheter Aortic Valve Replacement (TAVR)

    TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    The primary end point is the 5 year all-cause mortality

    Time frame: At 5 years

Secondary outcomes

  1. The composite of all-cause mortality, stroke and rehospitalization

    The composite of all-cause mortality, stroke, rehospitalization (procedure, valve and heart failure related) at 30 days, 1, 3, 5 years

    Time frame: At 30 days, 1, 3, 5 years

  2. The composite of device success

    The composite of device success at 30 days comprising the following: freedom from mortality, successful access, delivery of the device, and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication, intended performance of the valve (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation), according to the VARC-3 definition

    Time frame: At 30 days

  3. The durability performance of Sapien 3

    The durability performance of Sapien 3 at 1, 3, 5 years: bioprosthetic valve dysfunction (BVD, including SVD, non-SVD, endocarditis and thrombosis), moderate or severe hemodynamic valve deterioration (HVD), bioprosthetic valve failure (BVF) according to the VARC-3 definition, EOA/mean gradient (MG) change over follow up

    Time frame: At 1, 3, 5 years

  4. Annular rupture

    The incidence of annular rupture

    Time frame: At 1 day of discharge

  5. Paravalvular leakage

    The incidence of paravalvular leakage

    Time frame: At 1 day of discharge, 30 days, 1, 3, 5 years

  6. Technical success

    Technical success (at exit from procedure room): * freedom from mortality * successful access, delivery of the device, and retrieval of the delivery system * correct positioning of a single prosthetic heart valve into the proper anatomical location * freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication

    Time frame: At exit from procedure room

  7. Procedural success

    Procedural success at 30 days defined as meeting all of the following: * Device success * No device or procedure related SAE's as follows: 1. Life-threatening bleed (BARC 3b or greater) 2. Major vascular or cardiac structural complications requiring unplanned reintervention or surgery 3. Stage 2 or 3 AKI (includes new dialysis) 4. MI or need for PCI/CABG 5. Severe heart failure or hypotension requiring IV inotrope \>12 hours, ultrafiltration or mechanical circulatory support 6. Prolonged intubation \> 48 hours 7. Need for a permanent pacemaker implant or continuous, new onset atrial fibrillation

    Time frame: At 30 days

  8. Mortality (all cause & cardiovascular)

    The incidence of mortality (all cause \& cardiovascular)

    Time frame: At 30 days, 1, 3, 5 years

  9. Stroke (disabling and nondisabling)

    The incidence of stroke (disabling and nondisabling)

    Time frame: At 30 days, 1, 3, 5 years

  10. Rehospitalization (procedure, valve and heart failure related)

    The incidence of rehospitalization (procedure, valve and heart failure related)

    Time frame: At 30 days, 1, 3, 5 years

  11. Major vascular complication

    The incidence of major vascular complication

    Time frame: At 30 days, 1, 3, 5 years

  12. Major or life-threatening bleeding

    The incidence of major or life-threatening bleeding

    Time frame: At 30 days, 1, 3, 5 years

  13. Myocardial infarction

    The incidence of myocardial infarction

    Time frame: At 30 days, 1, 3, 5 years

  14. Acute kidney injury stage 2 or 3

    The incidence of acute kidney injury stage 2 or 3

    Time frame: At 30 days, 1, 3, 5 years

  15. Need for a permanent pacemaker

    The incidence of permanent pacemaker implantation

    Time frame: At 30 days, 1, 3, 5 years

  16. New onset atrial fibrillation

    The incidence of new onset atrial fibrillation

    Time frame: At 30 days, 1, 3, 5 years

  17. Valve endocarditis

    The incidence of valve endocarditis

    Time frame: At 30 days, 1, 3, 5 years

  18. Valve thrombosis

    The incidence of valve thrombosis

    Time frame: At 30 days, 1, 3, 5 years

  19. New York Heart Association class

    The changes in New York Heart Association class

    Time frame: At 30 days, 1, 3, 5 years

  20. Patient-prosthesis mismatch

    The incidence of patient-prosthesis mismatch

    Time frame: At 30 days, 1, 3, 5 years

  21. Health status as evaluated by Quality of Life questionnaires - KCCQ

    The changes in Health status as evaluated by Quality of Life questionnaires - KCCQ

    Time frame: At baseline, 30 days, 1, 3, 5 years

07

Study locations

2 of 4 sites recruiting
  • Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical University
    Xi'an, Shaanxi 710032, China
    Recruiting
    • Jian Yang, MD, PhD · Contactyangjian@fmmu.edu.cn · +8613892828016
    • Meng en Zhai, PhD · Contactzhaimengen@126.com · +8617782801836
    • Jian Yang, MD, PhD · Principal investigator
    • Meng en Zhai, PhD · Sub investigator
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
    Not yet recruiting
    • Yingqiang Guo, MD, PhD · Contact
    • Yingqiang Guo, MD, PhD · Principal investigator
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
    Not yet recruiting
    • Xiangbin Pan, MD, PhD · Contact
    • Xiangbin Pan, MD, PhD · Principal investigator
  • Shanghai Zhongshan Hospital, Fudan University
    Shanghai, China
    Recruiting
    • Lai Wei, MD, PhD · Contact
    • Lai Wei, MD, PhD · Principal investigator
08

References and documents

Publications

  • Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, Dudek D, Gilard M, Gorog DA, Grapsa J, Grove EL, Lancellotti P, Petronio AS, Rubboli A, Torracca L, Vilahur G, Witkowski A, Mehilli J. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J. 2021 Jun 14;42(23):2265-2269. doi: 10.1093/eurheartj/ehab196. PubMed 33822924 ↗
  • Gupta T, DeVries JT, Gilani F, Hassan A, Ross CS, Dauerman HL. Temporal Trends in Transcatheter Aortic Valve Replacement for Isolated Severe Aortic Stenosis. J Soc Cardiovasc Angiogr Interv. 2024 Apr 5;3(7):101861. doi: 10.1016/j.jscai.2024.101861. eCollection 2024 Jul. No abstract available. PubMed 39132009 ↗
  • Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National Trends in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. J Am Coll Cardiol. 2022 Nov 22;80(21):2054-2056. doi: 10.1016/j.jacc.2022.08.787. Epub 2022 Sep 16. No abstract available. PubMed 36122626 ↗
  • Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchetche D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16. PubMed 30883053 ↗
  • Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16. PubMed 30883058 ↗
  • Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP; SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017 Apr 6;376(14):1321-1331. doi: 10.1056/NEJMoa1700456. Epub 2017 Mar 17. PubMed 28304219 ↗
  • Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG; PARTNER 2 Investigators. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016 Apr 28;374(17):1609-20. doi: 10.1056/NEJMoa1514616. Epub 2016 Apr 2. PubMed 27040324 ↗
  • Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011 Jun 9;364(23):2187-98. doi: 10.1056/NEJMoa1103510. Epub 2011 Jun 5. PubMed 21639811 ↗
  • Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22. PubMed 20961243 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) would not be shared, according to local authority data privacy policy.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2031, 74 months after the start.

Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 74 months is above that.

Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2025
First posted
Feb 17, 2025
StartActual
Apr 24, 2025
Primary completionEst.
Jun 30, 2031
CompletionEst.
Jun 30, 2031
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830499
Lead sponsor
Xijing Hospital
Collaborators
Shanghai Zhongshan Hospital, Fu Wai Hospital, Beijing, China, West China Hospital
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Apr 24, 2025
Primary completion
Jun 30, 2031 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
May 27, 2026

Study contacts

Jian Yang, MD, PhD
Contact
yangjian@fmmu.edu.cn
+8613892828016
Meng en Zhai, PhD
Contact
zhaimengen@126.com
+8617782801836
Jian Yang, MD, PhD
principal investigator · Department of Cardiovascular Surgery of Xijing Hospital, Air Force Military Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion